{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:35:17Z","timestamp":1793306117036,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Metab"],"DOI":"10.1038\/s42255-026-01643-4","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:06:32Z","timestamp":1790859992000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial"],"prefix":"10.1038","author":[{"given":"Mijra","family":"Koning","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artemiy","family":"Kovynev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5099-3421","authenticated-orcid":false,"given":"Marcos F.","family":"Fondevila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza J. M.","family":"Ruhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel C.","family":"Mommersteeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ramakers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9243-0037","authenticated-orcid":false,"given":"Barbara A.","family":"Hutten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Verwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marije","family":"Vlug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teaco","family":"Kuiper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Vrieze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Bizino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annewieke","family":"van den Beld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luuk","family":"Berk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Boerlage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quinten J. J.","family":"Augustijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8713-1481","authenticated-orcid":false,"given":"Willem Pieter","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weena J.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djuna","family":"Cahen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Verdonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter J.","family":"de Jonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandjai","family":"Ramsoekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8611-840X","authenticated-orcid":false,"given":"Michail","family":"Doukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne M. M.","family":"Vermorgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Verheij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5114-7799","authenticated-orcid":false,"given":"Ulrich","family":"Beuers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2179-1385","authenticated-orcid":false,"given":"R. B.","family":"Takkenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques J. G.","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2784-4046","authenticated-orcid":false,"given":"Geert R. A. M.","family":"D\u2019Haens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost P. H.","family":"Drenth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Tchkonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6281-825X","authenticated-orcid":false,"given":"Bernd","family":"Schnabl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Kirkland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6015-4656","authenticated-orcid":false,"given":"Abraham S.","family":"Meijnikman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"1643_CR1","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/s42255-022-00620-x","volume":"4","author":"RK Baboota","year":"2022","unstructured":"Baboota, R. K. et al. BMP4 and Gremlin 1 regulate hepatic cell senescence during clinical progression of NAFLD\/NASH. Nat. Metab. 4, 1007\u20131021 (2022).","journal-title":"Nat. Metab."},{"key":"1643_CR2","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1097\/HEP.0000000000000326","volume":"77","author":"K Du","year":"2023","unstructured":"Du, K. et al. Targeting YAP-mediated HSC death susceptibility and senescence for treatment of liver fibrosis. Hepatology 77, 1998\u20132015 (2023).","journal-title":"Hepatology"},{"key":"1643_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57616-w","volume":"16","author":"K Du","year":"2025","unstructured":"Du, K. et al. Targeting senescent hepatocytes for treatment of metabolic dysfunction-associated steatotic liver disease and multi-organ dysfunction. Nat. Commun. 16, 3038 (2025).","journal-title":"Nat. Commun."},{"key":"1643_CR4","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","volume":"31","author":"ZM Younossi","year":"2025","unstructured":"Younossi, Z. M., Kalligeros, M. & Henry, L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin. Mol. Hepatol. 31, S32\u2013s50 (2025).","journal-title":"Clin. Mol. Hepatol."},{"key":"1643_CR5","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s12072-023-10550-9","volume":"17","author":"WL Chan","year":"2023","unstructured":"Chan, W. L. et al. Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy. Hepatol. Int. 17, 870\u2013881 (2023).","journal-title":"Hepatol. Int."},{"key":"1643_CR6","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal, A. J. et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N. Engl. J. Med. 385, 1559\u20131569 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1643_CR7","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai, P. S. et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 65, 1557\u20131565 (2017).","journal-title":"Hepatology"},{"key":"1643_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jhep.2024.03.014","volume":"81","author":"CN Yashaswini","year":"2024","unstructured":"Yashaswini, C. N. et al. Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatohepatitis. J. Hepatol. 81, 207\u2013217 (2024).","journal-title":"J. Hepatol."},{"key":"1643_CR9","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jhep.2012.10.031","volume":"58","author":"A Aravinthan","year":"2013","unstructured":"Aravinthan, A. et al. Hepatocyte senescence predicts progression in non-alcohol-related fatty liver disease. J. Hepatol. 58, 549\u2013556 (2013).","journal-title":"J. Hepatol."},{"key":"1643_CR10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/hep.30834","volume":"71","author":"AM Papatheodoridi","year":"2020","unstructured":"Papatheodoridi, A. M., Chrysavgis, L., Koutsilieris, M. & Chatzigeorgiou, A. The role of senescence in the development of nonalcoholic fatty liver disease and progression to nonalcoholic steatohepatitis. Hepatology 71, 363\u2013374 (2020).","journal-title":"Hepatology"},{"key":"1643_CR11","doi-asserted-by":"publisher","first-page":"e180310","DOI":"10.1172\/JCI180310","volume":"134","author":"JH Jun","year":"2024","unstructured":"Jun, J. H. et al. The senescence-associated secretome of Hedgehog-deficient hepatocytes drives MASLD progression. J. Clin. Invest. 134, e180310 (2024).","journal-title":"J. Clin. Invest."},{"key":"1643_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101657","volume":"8","author":"H Vu","year":"2026","unstructured":"Vu, H. et al. Progressive fibrosis in human MASLD is associated with spatially linked transcriptomic signatures of metabolic reprogramming and senescence. JHEP Rep. 8, 101657 (2026).","journal-title":"JHEP Rep."},{"key":"1643_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.cell.2022.11.001","volume":"186","author":"C L\u00f3pez-Ot\u00edn","year":"2023","unstructured":"L\u00f3pez-Ot\u00edn, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. Hallmarks of aging: an expanding universe. Cell 186, 243\u2013278 (2023).","journal-title":"Cell"},{"key":"1643_CR14","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.cell.2008.03.038","volume":"133","author":"JC Acosta","year":"2008","unstructured":"Acosta, J. C. et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133, 1006\u20131018 (2008).","journal-title":"Cell"},{"key":"1643_CR15","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s43587-024-00795-w","volume":"5","author":"H Yang","year":"2025","unstructured":"Yang, H. et al. Gut microbial-derived phenylacetylglutamine accelerates host cellular senescence. Nat. Aging 5, 401\u2013418 (2025).","journal-title":"Nat. Aging"},{"key":"1643_CR16","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1038\/s43587-023-00480-4","volume":"3","author":"C Anerillas","year":"2023","unstructured":"Anerillas, C. et al. The YAP\u2013TEAD complex promotes senescent cell survival by lowering endoplasmic reticulum stress. Nat. Aging 3, 1237\u20131250 (2023).","journal-title":"Nat. Aging"},{"key":"1643_CR17","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1016\/j.molcel.2022.07.017","volume":"82","author":"MC Lanz","year":"2022","unstructured":"Lanz, M. C. et al. Increasing cell size remodels the proteome and promotes senescence. Mol. Cell 82, 3255\u20133269 (2022).","journal-title":"Mol. Cell"},{"key":"1643_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56929-0","volume":"16","author":"J Joung","year":"2025","unstructured":"Joung, J. et al. Cell enlargement modulated by GATA4 and YAP instructs the senescence-associated secretory phenotype. Nat. Commun. 16, 1696 (2025).","journal-title":"Nat. Commun."},{"key":"1643_CR19","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nature24050","volume":"550","author":"Z Dou","year":"2017","unstructured":"Dou, Z. et al. Cytoplasmic chromatin triggers inflammation in senescence and cancer. Nature 550, 402\u2013406 (2017).","journal-title":"Nature"},{"key":"1643_CR20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41586-024-08317-9","volume":"637","author":"L Gu","year":"2025","unstructured":"Gu, L. et al. FBP1 controls liver cancer evolution from senescent MASH hepatocytes. Nature 637, 461\u2013469 (2025).","journal-title":"Nature"},{"key":"1643_CR21","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/s41586-023-06621-4","volume":"622","author":"S Victorelli","year":"2023","unstructured":"Victorelli, S. et al. Apoptotic stress causes mtDNA release during senescence and drives the SASP. Nature 622, 627\u2013636 (2023).","journal-title":"Nature"},{"key":"1643_CR22","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41581-022-00601-z","volume":"18","author":"W Huang","year":"2022","unstructured":"Huang, W., Hickson, L. J., Eirin, A., Kirkland, J. L. & Lerman, L. O. Cellular senescence: the good, the bad and the unknown. Nat. Rev. Nephrol. 18, 611\u2013627 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"1643_CR23","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s43018-023-00712-x","volume":"5","author":"S Chaib","year":"2024","unstructured":"Chaib, S. et al. The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2. Nat. Cancer 5, 448\u2013462 (2024).","journal-title":"Nat. Cancer"},{"key":"1643_CR24","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/s41580-024-00727-x","volume":"25","author":"B Wang","year":"2024","unstructured":"Wang, B., Han, J., Elisseeff, J. H. & Demaria, M. The senescence-associated secretory phenotype and its physiological and pathological implications. Nat. Rev. Mol. Cell Biol. 25, 958\u2013978 (2024).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1643_CR25","first-page":"2284","volume":"55","author":"E Wang","year":"1995","unstructured":"Wang, E. Senescent human fibroblasts resist programmed cell death, and failure to suppress bcl2 is involved. Cancer Res. 55, 2284\u20132292 (1995).","journal-title":"Cancer Res."},{"key":"1643_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101478","volume":"7","author":"T Rubio-Tom\u00e1s","year":"2025","unstructured":"Rubio-Tom\u00e1s, T. et al. GDF15 is associated with hepatocellular senescence and correlates with mortality in patients with alcohol-associated hepatitis. JHEP Rep. 7, 101478 (2025).","journal-title":"JHEP Rep."},{"key":"1643_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100286","volume":"3","author":"N Cazzagon","year":"2021","unstructured":"Cazzagon, N. et al. Cholangiocyte senescence in primary sclerosing cholangitis is associated with disease severity and prognosis. JHEP Rep. 3, 100286 (2021).","journal-title":"JHEP Rep."},{"key":"1643_CR28","doi-asserted-by":"publisher","first-page":"e170320","DOI":"10.1172\/jci.insight.170320","volume":"8","author":"N Jalan-Sakrikar","year":"2023","unstructured":"Jalan-Sakrikar, N. et al. Telomere dysfunction promotes cholangiocyte senescence and biliary fibrosis in primary sclerosing cholangitis. JCI Insight 8, e170320 (2023).","journal-title":"JCI Insight"},{"key":"1643_CR29","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/hep.29464","volume":"67","author":"A Moncsek","year":"2018","unstructured":"Moncsek, A. et al. Targeting senescent cholangiocytes and activated fibroblasts with B-cell lymphoma-extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2(\u2212\/\u2212)) mice. Hepatology 67, 247\u2013259 (2018).","journal-title":"Hepatology"},{"key":"1643_CR30","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1038\/s41591-022-01923-y","volume":"28","author":"S Chaib","year":"2022","unstructured":"Chaib, S., Tchkonia, T. & Kirkland, J. L. Cellular senescence and senolytics: the path to the clinic. Nat. Med. 28, 1556\u20131568 (2022).","journal-title":"Nat. Med."},{"key":"1643_CR31","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1016\/j.cmet.2025.10.009","volume":"37","author":"M Suda","year":"2025","unstructured":"Suda, M. et al. Endothelial senescent-cell-specific clearance alleviates metabolic dysfunction in obese mice. Cell Metab. 37, 2455\u20132465 (2025).","journal-title":"Cell Metab."},{"key":"1643_CR32","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/j.cmet.2024.07.006","volume":"36","author":"B Wang","year":"2024","unstructured":"Wang, B. et al. Intermittent clearance of p21-highly-expressing cells extends lifespan and confers sustained benefits to health and physical function. Cell Metab. 36, 1795\u20131805 (2024).","journal-title":"Cell Metab."},{"key":"1643_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15691","volume":"8","author":"M Ogrodnik","year":"2017","unstructured":"Ogrodnik, M. et al. Cellular senescence drives age-dependent hepatic steatosis. Nat. Commun. 8, 15691 (2017).","journal-title":"Nat. Commun."},{"key":"1643_CR34","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1038\/s41591-023-02543-w","volume":"29","author":"MM Gonzales","year":"2023","unstructured":"Gonzales, M. M. et al. Senolytic therapy in mild Alzheimer\u2019s disease: a phase 1 feasibility trial. Nat. Med. 29, 2481\u20132488 (2023).","journal-title":"Nat. Med."},{"key":"1643_CR35","doi-asserted-by":"publisher","first-page":"104481","DOI":"10.1016\/j.ebiom.2023.104481","volume":"90","author":"A Nambiar","year":"2023","unstructured":"Nambiar, A. et al. Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability. EBioMedicine 90, 104481 (2023).","journal-title":"EBioMedicine"},{"key":"1643_CR36","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ebiom.2019.08.069","volume":"47","author":"LJ Hickson","year":"2019","unstructured":"Hickson, L. J. et al. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine 47, 446\u2013456 (2019).","journal-title":"EBioMedicine"},{"key":"1643_CR37","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1038\/s41591-024-03096-2","volume":"30","author":"JN Farr","year":"2024","unstructured":"Farr, J. N. et al. Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial. Nat. Med. 30, 2605\u20132612 (2024).","journal-title":"Nat. Med."},{"key":"1643_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12950","volume":"18","author":"AK Palmer","year":"2019","unstructured":"Palmer, A. K. et al. Targeting senescent cells alleviates obesity-induced metabolic dysfunction. Aging Cell 18, e12950 (2019).","journal-title":"Aging Cell"},{"key":"1643_CR39","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/acel.12344","volume":"14","author":"Y Zhu","year":"2015","unstructured":"Zhu, Y. et al. The Achilles\u2019 heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 14, 644\u2013658 (2015).","journal-title":"Aging Cell"},{"key":"1643_CR40","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/joim.13141","volume":"288","author":"JL Kirkland","year":"2020","unstructured":"Kirkland, J. L. & Tchkonia, T. Senolytic drugs: from discovery to translation. J. Intern. Med. 288, 518\u2013536 (2020).","journal-title":"J. Intern. Med."},{"key":"1643_CR41","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13767","volume":"22","author":"MT Islam","year":"2023","unstructured":"Islam, M. T. et al. Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age. Aging Cell 22, e13767 (2023).","journal-title":"Aging Cell"},{"key":"1643_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25453-2","volume":"12","author":"EJ Novais","year":"2021","unstructured":"Novais, E. J. et al. Long-term treatment with senolytic drugs dasatinib and quercetin ameliorates age-dependent intervertebral disc degeneration in mice. Nat. Commun. 12, 5213 (2021).","journal-title":"Nat. Commun."},{"key":"1643_CR43","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/s41591-018-0092-9","volume":"24","author":"M Xu","year":"2018","unstructured":"Xu, M. et al. Senolytics improve physical function and increase lifespan in old age. Nat. Med. 24, 1246\u20131256 (2018).","journal-title":"Nat. Med."},{"key":"1643_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2026.101737","volume":"8","author":"DG Tiniakos","year":"2026","unstructured":"Tiniakos, D. G. et al. The Elucidating Pathways of Steatohepatitis (EPoS) staging system: a reproducible 7-tiered fibrosis scoring system in MASLD. JHEP Rep. 8, 101737 (2026).","journal-title":"JHEP Rep."},{"key":"1643_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32552-1","volume":"13","author":"D Saul","year":"2022","unstructured":"Saul, D. et al. A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues. Nat. Commun. 13, 4827 (2022).","journal-title":"Nat. Commun."},{"key":"1643_CR46","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nature10599","volume":"479","author":"TW Kang","year":"2011","unstructured":"Kang, T. W. et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 479, 547\u2013551 (2011).","journal-title":"Nature"},{"key":"1643_CR47","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison, S. A. et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N. Engl. J. Med. 390, 497\u2013509 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1643_CR48","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba, R. et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N. Engl. J. Med. 391, 299\u2013310 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1643_CR49","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal, A. J. et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N. Engl. J. Med. 392, 2089\u20132099 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1643_CR50","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.jhep.2024.10.044","volume":"82","author":"HY Kim","year":"2025","unstructured":"Kim, H. Y. et al. Multi-modal analysis of human hepatic stellate cells identifies novel therapeutic targets for metabolic dysfunction-associated steatotic liver disease. J. Hepatol. 82, 882\u2013897 (2025).","journal-title":"J. Hepatol."},{"key":"1643_CR51","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.ebiom.2018.12.052","volume":"40","author":"JN Justice","year":"2019","unstructured":"Justice, J. N. et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine 40, 554\u2013563 (2019).","journal-title":"EBioMedicine"},{"key":"1643_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13192-4","volume":"10","author":"O Karin","year":"2019","unstructured":"Karin, O., Agrawal, A., Porat, Z., Krizhanovsky, V. & Alon, U. Senescent cell turnover slows with age providing an explanation for the Gompertz law. Nat. Commun. 10, 5495 (2019).","journal-title":"Nat. Commun."},{"key":"1643_CR53","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/hep.22742","volume":"49","author":"DC Rockey","year":"2009","unstructured":"Rockey, D. C., Caldwell, S. H., Goodman, Z. D., Nelson, R. C. & Smith, A. D. Liver biopsy. Hepatology 49, 1017\u20131044 (2009).","journal-title":"Hepatology"},{"key":"1643_CR54","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.jhep.2025.09.019","volume":"84","author":"C Lackner","year":"2026","unstructured":"Lackner, C. et al. Consensus position statements for the standardized application of histological grading and staging systems in MASH clinical trials. J. Hepatol. 84, 693\u2013701 (2026).","journal-title":"J. Hepatol."}],"container-title":["Nature Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42255-026-01643-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42255-026-01643-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42255-026-01643-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:06:33Z","timestamp":1790859993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42255-026-01643-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":54,"alternative-id":["1643"],"URL":"https:\/\/doi.org\/10.1038\/s42255-026-01643-4","relation":{},"ISSN":["2522-5812"],"issn-type":[{"value":"2522-5812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"3 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.K. and A.S.M have no competing interests. B.S. has been consulting for Boehringer Ingelheim Pharma and Mabwell Therapeutics (previous 24\u2009months). B.S.\u2019s institution UC San Diego has received research support from Axial Biotherapeutics, Apollo Therapeutics, ChromoLogic, Intercept Pharmaceuticals and Prodigy Biotech (previous 24\u2009months). B.S. is founder of Nterica Bio. UC San Diego has filed several patents with B.S. as inventor. T.T. and J.L.K. have a financial interest related to this research, including patents and pending patents covering senolytic drugs and their uses held by Mayo Clinic. This research was conducted in compliance with Mayo Clinic and Cedars-Sinai conflict of interest policies The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}